U.S., Nov. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07932808) titled 'Naxitamab Enabled Transplant-Free Study in High-Risk Neuroblastoma' on Nov. 05.
Brief Summary: A prospective, multicenter, clinical trial in participants with high-risk neuroblastoma that have completed induction therapy, evaluating the feasibility, efficacy, and toxicity of using anti-GD2 chemo-immunotherapy (naxitamab/irinotecan/temozolomide/GM-CSF) as consolidation followed by standard radiation, then standard anti-GD2 immunotherapy, and 2 years of DFMO maintenance.
Study Start Date: Nov. 26
Study Type: INTERVENTIONAL
Condition:
Neuroblastoma
Intervention:
DRUG: Naxitamab and GM-CSF in combination with irinotecan and temozo...